Valuation: Biocorrx Inc

Market Cap 75.54L 65.67L 61.13L 56.12L 1.06Cr 72Cr 1.08Cr 7.21Cr 2.83Cr 36Cr 2.84Cr 2.77Cr 120.39Cr P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 95.56L 83.07L 77.32L 70.99L 1.34Cr 91Cr 1.36Cr 9.11Cr 3.58Cr 45Cr 3.59Cr 3.51Cr 152.28Cr EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 09/11/2020
President 77 05/01/2024
Director TitleAgeSince
Director/Board Member 58 07/03/2013
Chairman 57 -
Director/Board Member 77 01/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 75.54L
+0.05%-3.07%+67.17%+36.67% 13TCr
+2.63%+5.34%+12.78%+49.45% 8.72TCr
+1.52%+1.60%+8.36%+58.25% 2.88TCr
-0.70%+2.26%+36.38%+72.91% 2.57TCr
+1.49%+2.55%-8.65%-16.55% 2.19TCr
+0.69%+9.25%+61.16%+243.83% 2.05TCr
+2.31%+1.98%+73.38%+135.45% 1.54TCr
+0.43%+3.77%+6.91%-1.31% 1.5TCr
+2.83%+2.10%+3.44%-5.23% 1.36TCr
Average -0.89%+3.25%+28.99%+63.72% 4.01TCr
Weighted average by Cap. +0.87%+1.64%+37.61%+53.67%

Financials

2024 2025
Net sales 7.66T 6.66T 6.2T 5.69T 10.75T 7L 10.92T 73.11T 28.69T 4L 28.79T 28.15T 12.21L 8L 7L 6L 6L 11.18L 7.61Cr 11.36L 76.04L 29.84L 3.79Cr 29.94L 29.28L 13Cr
Net income -51.06L -44.39L -41.32L -37.93L -71.63L -49Cr -72.74L -4.87Cr -1.91Cr -24Cr -1.92Cr -1.88Cr -81Cr -34.4L -29.91L -27.84L -25.56L -48.26L -33Cr -49.01L -3.28Cr -1.29Cr -16Cr -1.29Cr -1.26Cr -55Cr
Net Debt 27.18L 23.63L 21.99L 20.19L 38.13L 26Cr 38.73L 2.59Cr 1.02Cr 13Cr 1.02Cr 99.85L 43Cr 20.01L 17.4L 16.19L 14.87L 28.08L 19Cr 28.51L 1.91Cr 74.91L 9.51Cr 75.16L 73.51L 32Cr
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-